

EXPANDED INDICATION FOR MENACTRA®

The FDA has granted licensure expanding the indication for Menactra® to include a 2 dose schedule for infants and children 9 months through 23 months of age. This is the first US approval of a meningococcal vaccine for this age group. Menactra® is now the meningococcal vaccine with the broadest indication for the protection of patients 9 months through 55 years of age.